cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.13130/rd_unimi/gsbgp1/dm3s7m
title: Giugno_1889_Pagina_110.jpg

description: Bulletin of 1889/06/28
DOI: 10.25934/pr00012397
title: A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease

description: The primary purpose of this study was to assess the efficacy of ribociclib, as measured by progression free survival (PFS), in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who received no prior treatment for advanced disease.
DOI: 10.13130/rd_unimi/jvs9pt/hsneym
title: Giugno_1892_Pagina_068.jpg

description: Bulletin of 1892/06/17
DOI: 10.13130/rd_unimi/nsvbhr/g6dnxc
title: Giugno_1890_Pagina_095.jpg

description: Bulletin of 1890/06/24
DOI: 10.13130/rd_unimi/v8alup/z1y1tf
title: Giugno_1891_Pagina_092.jpg

description: Bulletin of 1891/06/23
DOI: 10.25934/pr00012398
title: A Prospective, Two-arm, Non Interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

description: This was a prospective, two-arm, non-interventional study of JAKAVI® (Ruxolitinib) in patients with myelofibrosis
DOI: 10.13130/rd_unimi/cbrkhv/hiobwu
title: Gennaio_1927_Pagina_085.jpg

description: Bulletin of 1927/01/22
DOI: 10.13130/rd_unimi/xu1sm0/l6q9pr
title: Giugno_1893_Pagina_070.jpg

description: Bulletin of 1893/06/18
DOI: 10.25574/03223
title: Chandra X-ray Observatory ObsId 03223

description: THE X-RAY STRUCTURE OF THE PROTOTYPE FOSSIL GROUP
DOI: 10.25934/pr00012399
title: A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction

description: The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).
DOI: 10.25934/pr00012400
title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 Weeks of Treatment, Compared to Placebo, and to Assess Long-term Safety, Tolerability, and Efficacy in Subjects With Moderate to Severe Chronic Palmoplantar Pustular Psoriasis - Amended With an Optional Extension Treatment Period of up to a Total of 148 Weeks

description: A one year study assessing the efficacy and safety of secukinumab compared with placebo in adult patients with moderate to severe palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a total of 148 weeks
DOI: 10.13130/rd_unimi/6np0bt/jskixd
title: Giugno_1894_Pagina_054.jpg

description: Bulletin of 1894/06/14
DOI: 10.13130/rd_unimi/awv4gb/fq1gx6
title: Giugno_1896_Pagina_048.jpg

description: Bulletin of 1896/06/12
DOI: 10.13130/rd_unimi/gsbgp1/f4yuvv
title: Giugno_1889_Pagina_111.jpg

description: Bulletin of 1889/06/28
DOI: 10.13130/rd_unimi/jvs9pt/itndli
title: Giugno_1892_Pagina_069.jpg

description: Bulletin of 1892/06/18
DOI: 10.13130/rd_unimi/nsvbhr/djkdra
title: Giugno_1890_Pagina_096.jpg

description: Bulletin of 1890/06/24
DOI: 10.13130/rd_unimi/rjrjox/wiumso
title: Maggio_1895_Pagina_021.jpg

description: Bulletin of 1895/05/06
DOI: 10.25574/03224
title: Chandra X-ray Observatory ObsId 03224

description: RXJ1720.1+2638: A NEARLY RELAXED CLUSTER WITH A FAST MOVING CORE?
DOI: 10.25934/pr00012401
title: An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy

description: This was a four part, phase I/II study aimed to evaluate the safety, tolerability and efficacy of combination of an anti-EGFR antibody panitumumab (P) either with a BRAF inhibitor (dabrafenib (D); GSK2118436) alone or with the combination of a BRAF inhibitor and a MEK inhibitor (trametinib (T); GSK1120212) in patients with BRAF-mutant V600E advanced or mCRC. The goal was to: 1) Determine RP2R/MTD for doublet (D+P) and triplet (D+T+P) combinations in Part 1; 2) Assess clinical activity for these combinations in Part 2; 3) Determine RP2R/MTD for double (T+P) combination in Part 4A, and assess clinical activity of this combination in two patient populations in Part 4B (patients with BRAF-V600E mutation-positive advanced or metastatic CRC and patients with advanced or metastatic CRC with secondary resistance to anti-EGFR therapy).
DOI: 10.25934/pr00012402
title: A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

description: Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
DOI: 10.13130/rd_unimi/v8alup/2wc5fc
title: Giugno_1891_Pagina_093.jpg

description: Bulletin of 1891/06/24
DOI: 10.13130/rd_unimi/xu1sm0/mgisld
title: Giugno_1893_Pagina_071.jpg

description: Bulletin of 1893/06/18
DOI: 10.25934/pr00012403
title: A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma

description: A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks. In patients with allergies, there is an exaggerated production of IgE in response to specific substances such as pollens. Omalizumab is a new drug that inactivates IgE. This study tested the safety and efficacy of omalizumab against asthma attacks in children with allergic asthma.
DOI: 10.13130/rd_unimi/6np0bt/d1hnio
title: Giugno_1894_Pagina_055.jpg

description: Bulletin of 1894/06/14
DOI: 10.13130/rd_unimi/awv4gb/pnnljw
title: Giugno_1896_Pagina_049.jpg

description: Bulletin of 1896/06/13
DOI: 10.13130/rd_unimi/gsbgp1/z60dxg
title: Giugno_1889_Pagina_112.jpg

description: Bulletin of 1889/06/28
DOI: 10.25934/pr00012404
title: Ph III, 28-wk, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess Efficacy, Safety, Tolerability of SC Omalizumab in Adults and Adolescents w/ Severe Persist. Allergic Asthma & Are Inadequately Controlled Despite GINA (2002) Step 4 Tx

description: The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.
DOI: 10.13130/rd_unimi/cbrkhv/zjueie
title: Gennaio_1927_Pagina_086.jpg

description: Bulletin of 1927/01/22
DOI: 10.13130/rd_unimi/nsvbhr/mlff5y
title: Giugno_1890_Pagina_097.jpg

description: Bulletin of 1890/06/25
DOI: 10.13130/rd_unimi/rjrjox/jlayb1
title: Maggio_1895_Pagina_024.jpg

description: Bulletin of 1895/05/06
DOI: 10.25574/03226
title: Chandra X-ray Observatory ObsId 03226

description: DETECTION OF HIGH REDSHIFT CLUSTER OF GALAXIES AROUND 3CR184
DOI: 10.25934/pr00012405
title: A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled,Multi-center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

description: This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots) and will test the hypothesis that omalizumab may reduce the rate of systemic reactions to immunotherapy in patients with persistent allergic asthma.
DOI: 10.13130/rd_unimi/jvs9pt/zlzykp
title: Giugno_1892_Pagina_070.jpg

description: Bulletin of 1892/06/18
DOI: 10.13130/rd_unimi/v8alup/ybyuic
title: Giugno_1891_Pagina_094.jpg

description: Bulletin of 1891/06/24
DOI: 10.25934/pr00012406
title: A Randomized, 20 Week, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Combination With Depigoid, Versus Depigoid Only, in Adult and Adolescent Patients With Seasonal Allergic Asthma and Comorbid Seasonal Allergic Rhinoconjunctivitis - Open-label Depigoid Monotherapy Extension Periods 2007 and 2008-

description: Efficacy/ safety for the combination of anti-IgE (Omalizumab) and specific immunotherapy (Depigoid) in patients with not adequately controlled seasonal allergic asthma and comorbid seasonal allergic rhinoconjunctivitis.
DOI: 10.13130/rd_unimi/awv4gb/ttolkm
title: Giugno_1896_Pagina_050.jpg

description: Bulletin of 1896/06/13
DOI: 10.13130/rd_unimi/gsbgp1/bwifer
title: Giugno_1889_Pagina_113.jpg

description: Bulletin of 1889/06/29
DOI: 10.13130/rd_unimi/xu1sm0/sbrree
title: Giugno_1893_Pagina_072.jpg

description: Bulletin of 1893/06/18
DOI: 10.25934/pr00012407
title: A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD

description: This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
DOI: 10.3886/e237483
title: Code for: Tying with Network Effects

description: This is the code that generates Figure 2 in our paper "Tying with Network Effects." The code is created with Mathematica.
DOI: 10.13130/rd_unimi/6np0bt/hibhco
title: Giugno_1894_Pagina_056.jpg

description: Bulletin of 1894/06/14
DOI: 10.13130/rd_unimi/cbrkhv/zucidp
title: Gennaio_1927_Pagina_087.jpg

description: Bulletin of 1927/01/22
DOI: 10.13130/rd_unimi/rjrjox/skhijy
title: Maggio_1895_Pagina_026.jpg

description: Bulletin of 1895/05/07
DOI: 10.25574/03227
title: Chandra X-ray Observatory ObsId 03227

description: A SEARCH FOR SMALL-SCALE STRUCTURE IN THE RASSCALS GALAXY GROUPS
DOI: 10.25934/pr00012408
title: A Randomized, Subject and Investigator Blinded, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis

description: The main purpose of this phase 2 study was to assess the efficacy and safety of CMK389 in patients with atopic dermatitis.
DOI: 10.3886/e237483v1
title: Code for: Tying with Network Effects

description: This is the code that generates Figure 2 in our paper "Tying with Network Effects." The code is created with Mathematica.
DOI: 10.13130/rd_unimi/jvs9pt/wzcwae
title: Giugno_1892_Pagina_071.jpg

description: Bulletin of 1892/06/18
DOI: 10.13130/rd_unimi/nsvbhr/3fkc8p
title: Giugno_1890_Pagina_098.jpg

description: Bulletin of 1890/06/25
DOI: 10.25934/pr00012409
title: An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF).

description: The primary objective of this study was to collect additional safety of INC424 in patients with Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis, who either received prior treatment with commercially available agents or who have never received treatment.
DOI: 10.13130/rd_unimi/awv4gb/zl0bxk
title: Giugno_1896_Pagina_051.jpg

description: Bulletin of 1896/06/13
DOI: 10.13130/rd_unimi/gsbgp1/dywket
title: Giugno_1889_Pagina_114.jpg

description: Bulletin of 1889/06/29
DOI: 10.13130/rd_unimi/xu1sm0/cxbjz7
title: Giugno_1893_Pagina_073.jpg

description: Bulletin of 1893/06/19
DOI: 10.25934/pr00012410
title: VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

description: The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.
DOI: 10.25934/pr00012411
title: A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)

description: The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR\<0.05) AML (FLT3 mutant to wild type signal ratio below the 0.05 clinical cut-off).This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin or idarubicin and cytarabine for induction and intermediate-dose cytarabine for consolidation, and midostaurin single agent post-consolidation therapy in newly diagnosed patients with FLT3-MN (SR\<0.05) AML.
DOI: 10.13130/rd_unimi/6np0bt/pllkks
title: Giugno_1894_Pagina_057.jpg

description: Bulletin of 1894/06/15
DOI: 10.13130/rd_unimi/cbrkhv/eqtajt
title: Gennaio_1927_Pagina_088.jpg

description: Bulletin of 1927/01/22
DOI: 10.13130/rd_unimi/v8alup/8he0tq
title: Giugno_1891_Pagina_095.jpg

description: Bulletin of 1891/06/24
DOI: 10.25574/03228
title: Chandra X-ray Observatory ObsId 03228

description: THE CLUSTER ENVIRONMENTS OF OLD GALAXIES IN QUASAR FIELDS AT Z ~ 1.5
DOI: 10.13130/rd_unimi/nsvbhr/csowg7
title: Giugno_1890_Pagina_099.jpg

description: Bulletin of 1890/06/25
DOI: 10.13130/rd_unimi/rjrjox/nu6zlb
title: Maggio_1895_Pagina_014.jpg

description: Bulletin of 1895/05/04
DOI: 10.25934/pr00012412
title: A Randomized, Double-blind, Placebo Controlled, Single-dose Study to Assess the Initial Efficacy of Canakinumab (ACZ885) With Respect to the Adapted ACR Pediatric 30 Criteria in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations

description: This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare. Response to treatment will be according to the adapted American College of Rheumatology(ACR)Pediatric 30 criteria at Day 15.
DOI: 10.25934/pr00012413
title: A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations

description: This two-part study assessed the sustained efficacy of canakinumab in the double-blind Part II and the ability to taper steroids in the open label Part I.
DOI: 10.13130/rd_unimi/awv4gb/7ksnoq
title: Giugno_1896_Pagina_052.jpg

description: Bulletin of 1896/06/13
DOI: 10.13130/rd_unimi/gsbgp1/t7vazj
title: Giugno_1889_Pagina_115.jpg

description: Bulletin of 1889/06/29
DOI: 10.13130/rd_unimi/jvs9pt/omklh5
title: Giugno_1892_Pagina_072.jpg

description: Bulletin of 1892/06/18
DOI: 10.13130/rd_unimi/xu1sm0/qhrkud
title: Giugno_1893_Pagina_074.jpg

description: Bulletin of 1893/06/19
DOI: 10.25934/pr00012414
title: A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

description: This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours with progression despite LAR treatment.
DOI: 10.25574/03229
title: Chandra X-ray Observatory ObsId 03229

description: THE CLUSTER ENVIRONMENTS OF OLD GALAXIES IN QUASAR FIELDS AT Z ~ 1.5
DOI: 10.13130/rd_unimi/6np0bt/zbnsqb
title: Giugno_1894_Pagina_058.jpg

description: Bulletin of 1894/06/15
DOI: 10.13130/rd_unimi/cbrkhv/ftz3o5
title: Gennaio_1927_Pagina_089.jpg

description: Bulletin of 1927/01/23
DOI: 10.15468/dl.vzc4na
title: Occurrence Download

description: A dataset containing 920 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Ageneiosus inermis",
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 {
 "or" : [
 "CoordinateUncertaintyInMeters is less than 10000",
 "CoordinateUncertaintyInMeters is null"
 ]
 }
 ]
}

 The dataset includes 920 records from 61 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054867-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00012415
title: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.

description: Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).
DOI: 10.13130/rd_unimi/gsbgp1/yhrzrc
title: Giugno_1889_Pagina_116.jpg

description: Bulletin of 1889/06/29
DOI: 10.13130/rd_unimi/jvs9pt/ilmpef
title: Giugno_1892_Pagina_073.jpg

description: Bulletin of 1892/06/19
DOI: 10.13130/rd_unimi/rjrjox/nsln7q
title: Maggio_1895_Pagina_016.jpg

description: Bulletin of 1895/05/04
DOI: 10.13130/rd_unimi/v8alup/xnxtec
title: Giugno_1891_Pagina_096.jpg

description: Bulletin of 1891/06/24
DOI: 10.25934/pr00012416
title: A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

description: The purpose of this study was to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remained symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab and over placebo.The study population consisted of 1,079 male and female subjects aged ≥ 12 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-antihistamines.This was a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There was a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.
DOI: 10.13130/rd_unimi/nsvbhr/lwarf0
title: Giugno_1890_Pagina_100.jpg

description: Bulletin of 1890/06/25
DOI: 10.13130/rd_unimi/xu1sm0/vwaxjk
title: Giugno_1893_Pagina_075.jpg

description: Bulletin of 1893/06/19
DOI: 10.25934/pr00012417
title: A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Safety and Efficacy of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

description: The purpose of this study was to establish safety and efficacy of ligelizumab in adolescent and adult subjects with Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab and over placebo.The study population consisted of 1,072 male and female subjects aged ≥ 12 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-antihistamines.This was a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There was a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.
DOI: 10.13130/rd_unimi/6np0bt/l7go60
title: Giugno_1894_Pagina_059.jpg

description: Bulletin of 1894/06/15
DOI: 10.13130/rd_unimi/awv4gb/tyxuf9
title: Giugno_1896_Pagina_053.jpg

description: Bulletin of 1896/06/14
DOI: 10.13130/rd_unimi/cbrkhv/npjd5g
title: Gennaio_1927_Pagina_090.jpg

description: Bulletin of 1927/01/23
DOI: 10.25574/03230
title: Chandra X-ray Observatory ObsId 03230

description: A STUDY OF MERGER SIGNATURES IN NEARBY GALAXY CLUSTERS: CONSTRAINTS ON ICM PHYSICS AND STRUCTURE FORMATION SCENARIOS
DOI: 10.25934/pr00012418
title: Investigator- and Subject-blinded, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy Trial of CFZ533 in Pediatric and Young Adult Subjects With New Onset Type 1 Diabetes (T1DM)

description: The study was a Phase 2, multicounty, multicenter, non-confirmatory, investigator- and subject masked, randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CFZ533 on preservation of residual pancreatic β-cell function in new onset T1DM in pediatric and young adult subjects.
DOI: 10.13130/rd_unimi/jvs9pt/efxqee
title: Giugno_1892_Pagina_074.jpg

description: Bulletin of 1892/06/19
DOI: 10.13130/rd_unimi/rjrjox/9abbch
title: Maggio_1895_Pagina_032.jpg

description: Bulletin of 1895/05/08
DOI: 10.13130/rd_unimi/v8alup/feqjin
title: Giugno_1891_Pagina_097.jpg

description: Bulletin of 1891/06/25
DOI: 10.25934/pr00012419
title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite H1 Antihistamine Therapy

description: This was a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult participants 12 - 75 years who received the diagnosis of refractory chronic spontaneous uriticaria and who remained symptomatic despite standard-dosed non-sedating H1 antihistamine treatment.
DOI: 10.13130/rd_unimi/gsbgp1/cixbnv
title: Giugno_1889_Pagina_117.jpg

description: Bulletin of 1889/06/30
DOI: 10.13130/rd_unimi/nsvbhr/peyd4l
title: Giugno_1890_Pagina_101.jpg

description: Bulletin of 1890/06/26